No Data
No Data
Axsome Therapeutics, Inc. (NASDAQ:AXSM): Is Breakeven Near?
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $124
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), Zymeworks (ZYME) and Axsome Therapeutics (AXSM)
Positive Outlook for Axsome Therapeutics: Buy Rating Backed by Promising AXS-05 Prospects
Axsome Therapeutics: Promising Growth Trajectory Justifies Buy Rating Amidst Auvelity's Commercial Success
Express News | Axsome Therapeutics Inc : Mizuho Raises Target Price to $124 From $106